Envista Holdings Corp NVST
Envista is a global family of more than 30 trusted dental brands, including Nobel Biocare, Ormco, DEXIS, and Kerr, united by a shared purpose: to partner with professionals to improve lives. We help our customers deliver the best possible patient care through industry-leading products, solutions, and technology. Our comprehensive portfolio, including dental implants and treatment options, orthodontics, and digital imaging technologies, covers a wide range of dentists' clinical needs for diagnosing, treating, and preventing dental conditions as well as improving the human smile. We further support the dental community with leading solutions in restoratives, endodontics, rotary, infection prevention, and loupes.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.72B | $2.51B | $2.57B | $2.57B | $2.51B | $1.93B | $2.28B | $2.84B | $2.81B | — |
| Cost of revenue | $1.23B | $1.14B | $1.13B | $1.09B | $1.08B | $874.3M | $935.6M | $1.24B | $1.19B | — |
| Gross profit | $1.49B | $1.37B | $1.44B | $1.47B | $1.43B | $1.05B | $1.35B | $1.60B | $1.62B | — |
| R&D | $114.0M | $99.1M | $93.8M | $100.1M | $100.5M | $86.7M | $133.1M | $172.0M | $172.4M | — |
| SG&A | $1.16B | $1.16B | $1.06B | $1.06B | $1.02B | $924.6M | $980.4M | $1.13B | $1.06B | — |
| Total operating expenses | — | $2.27B | $2.18B | $2.13B | — | — | — | — | — | — |
| Operating income | $216.1M | -$1.04B | $31.5M | $319.2M | $306.2M | $43.5M | $235.7M | $298.4M | $386.6M | — |
| Interest expense | — | — | $63.4M | $38.4M | $54.1M | $62.5M | $3.5M | $0 | $0 | — |
| Pre-tax income | $177.2M | -$1.08B | -$54.9M | $283.9M | $254.5M | -$20.0M | $233.7M | $301.1M | $386.7M | — |
| Income tax | $130.2M | $33.9M | $45.3M | $45.9M | $9.0M | $62.5M | $49.6M | $70.4M | $85.6M | — |
| Net income | $47.0M | -$1.12B | -$100.2M | $243.1M | $340.5M | $33.3M | $217.6M | $230.7M | $301.1M | — |
| EPS, basic | 0.28 | -6.50 | -0.60 | 1.49 | 2.11 | 0.21 | 1.60 | 1.80 | 2.35 | — |
| EPS, diluted | 0.28 | -6.50 | -0.60 | 1.37 | 1.92 | 0.20 | 1.60 | 1.80 | 2.35 | — |
| Shares, diluted (wtd. avg.) | $169.2M | $172.2M | $166.9M | $177.6M | $177.6M | $164.1M | $136.4M | $127.9M | $127.9M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $1.21B | $1.07B | $940.0M | $606.9M | $1.07B | $888.9M | $211.2M | $0 | $0 | $0 |
| Receivables | $429.6M | $363.0M | $407.5M | $393.5M | $331.9M | $301.7M | $443.6M | $459.8M | — | — |
| Inventory | $288.1M | $241.0M | $258.8M | $300.8M | $263.8M | $216.0M | $277.9M | $278.7M | — | — |
| Total current assets | $2.03B | $1.79B | $1.74B | $1.42B | $1.84B | $1.59B | $1.00B | $786.8M | — | — |
| Property, plant and equipment | $296.8M | $277.0M | $309.6M | $293.6M | $264.1M | $274.6M | $290.3M | $261.6M | $231.2M | — |
| Goodwill | $2.36B | $2.26B | $3.29B | $3.50B | $3.13B | $3.21B | $3.31B | $3.33B | $3.37B | — |
| Other intangibles | $627.2M | $649.9M | $954.0M | $1.09B | $1.05B | $1.15B | $1.29B | $1.39B | — | — |
| Total assets | $5.68B | $5.35B | $6.61B | $6.59B | $6.57B | $6.88B | $6.16B | $5.84B | $5.99B | — |
| Short-term debt | $0 | $116.0M | $115.3M | $510.0M | $432.4M | $886.8M | $3.9M | $0 | — | — |
| Total current liabilities | $852.6M | $878.7M | $780.8M | $1.24B | $1.21B | $1.68B | $709.2M | $641.0M | — | — |
| Long-term debt | $1.45B | $1.28B | $1.40B | $870.7M | $883.4M | $907.7M | $1.32B | $0 | — | — |
| Retained earnings | -$440.4M | -$487.4M | $631.2M | $731.4M | $466.9M | $126.4M | $93.1M | $0 | — | — |
| Total equity | $3.11B | $2.93B | $4.17B | $4.21B | $4.06B | $3.72B | $3.54B | $4.82B | — | — |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $275.7M | $336.5M | $275.7M | $182.7M | $361.6M | $283.9M | $397.5M | $400.1M | $359.1M | — |
| Depreciation and amortisation | $116.0M | $123.1M | $135.6M | $137.8M | $117.8M | $121.7M | $120.4M | $130.0M | $121.4M | — |
| Stock-based compensation | $37.6M | $35.3M | $30.7M | $30.5M | $28.2M | $22.6M | $18.4M | — | — | — |
| Capital expenditure | $45.3M | $33.8M | $58.2M | $75.7M | $54.7M | $47.7M | $77.8M | $72.2M | $48.9M | — |
| Investing cash flow | -$51.1M | -$54.6M | -$62.4M | -$657.3M | $262.7M | -$69.1M | -$78.4M | -$75.5M | -$54.9M | — |
| Financing cash flow | -$170.9M | -$103.7M | $118.9M | $12.5M | -$465.6M | $492.5M | -$107.7M | -$324.6M | -$304.2M | — |
| Buybacks | $174.0M | $5.3M | — | — | — | — | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001757073-26-000031.
Others in SIC 3843
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| XRAY | DENTSPLY SIRONA Inc. | $2.27B | — | -3.0% |